Related Experiment Video
Updated: May 16, 2025

08:25
Identification of Circular RNAs using RNA Sequencing
Published on: November 14, 2019
12.1K
A circular RNA in neuroendocrine carcinomas
1Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215, USA.
Cancer Cell
|April 18, 2025
Summary
Small cell lung cancer and neuroendocrine prostate cancer rely on a circular RNA, circRMST, to maintain their neuroendocrine characteristics. This RNA binds transcription factors, essential for promoting the ASCL1 gene expression driving these cancers.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Small cell lung cancer (SCLC) and neuroendocrine prostate cancer (NEPC) are aggressive malignancies.
- The molecular drivers of neuroendocrine cancer phenotypes are not fully understood.
- Circular RNAs (circRNAs) are emerging as key regulators in various biological processes, including cancer.
Purpose of the Study:
- To investigate the role of circRNAs in SCLC and NEPC.
- To identify specific circRNAs that regulate the neuroendocrine phenotype in these cancers.
- To elucidate the molecular mechanisms by which circRNAs influence cancer progression.
Main Methods:
- Analysis of circRNA expression profiles in SCLC and NEPC patient samples.
- Functional studies using cell lines and animal models to assess the impact of circRMST.
- RNA-binding assays and gene expression analysis to determine the mechanism of action.
Main Results:
- circRMST was found to be highly expressed in both SCLC and NEPC.
- Knockdown of circRMST impaired the neuroendocrine phenotype and tumor growth.
- circRMST was shown to bind lineage transcription factors, promoting ASCL1 expression.
Conclusions:
- circRMST is a critical regulator of the neuroendocrine phenotype in SCLC and NEPC.
- circRMST represents a potential therapeutic target for these cancers.
- Targeting circRMST may offer a novel strategy for treating neuroendocrine malignancies.
Related Concept Videos
lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K

